Spruce Biosciences (SPRB) Competitors $0.07 0.00 (-0.69%) As of 12:29 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SPRB vs. TRIB, ATHA, BGXX, BCDA, EQ, SNSE, LPTX, BTAI, XFOR, and PHXMShould you be buying Spruce Biosciences stock or one of its competitors? The main competitors of Spruce Biosciences include Trinity Biotech (TRIB), Athira Pharma (ATHA), Bright Green (BGXX), BioCardia (BCDA), Equillium (EQ), Sensei Biotherapeutics (SNSE), Leap Therapeutics (LPTX), BioXcel Therapeutics (BTAI), X4 Pharmaceuticals (XFOR), and PHAXIAM Therapeutics (PHXM). These companies are all part of the "pharmaceutical products" industry. Spruce Biosciences vs. Its Competitors Trinity Biotech Athira Pharma Bright Green BioCardia Equillium Sensei Biotherapeutics Leap Therapeutics BioXcel Therapeutics X4 Pharmaceuticals PHAXIAM Therapeutics Spruce Biosciences (NASDAQ:SPRB) and Trinity Biotech (NASDAQ:TRIB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability. Do institutionals & insiders believe in SPRB or TRIB? 91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are held by institutional investors. 6.9% of Spruce Biosciences shares are held by insiders. Comparatively, 8.2% of Trinity Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has stronger earnings and valuation, SPRB or TRIB? Trinity Biotech has higher revenue and earnings than Spruce Biosciences. Trinity Biotech is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpruce Biosciences$4.91M0.62-$47.92M-$1.32-0.05Trinity Biotech$61.56M0.21-$31.79M-$2.82-0.25 Do analysts recommend SPRB or TRIB? Spruce Biosciences presently has a consensus price target of $1.75, indicating a potential upside of 2,317.13%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Spruce Biosciences is more favorable than Trinity Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spruce Biosciences 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Trinity Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer SPRB or TRIB? In the previous week, Spruce Biosciences and Spruce Biosciences both had 1 articles in the media. Spruce Biosciences' average media sentiment score of 0.00 equaled Trinity Biotech'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spruce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Trinity Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, SPRB or TRIB? Spruce Biosciences has a beta of 2.4, indicating that its stock price is 140% more volatile than the S&P 500. Comparatively, Trinity Biotech has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Is SPRB or TRIB more profitable? Trinity Biotech has a net margin of -51.64% compared to Spruce Biosciences' net margin of -555.23%. Trinity Biotech's return on equity of 0.00% beat Spruce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Spruce Biosciences-555.23% -62.10% -47.49% Trinity Biotech -51.64%N/A -27.43% SummarySpruce Biosciences beats Trinity Biotech on 7 of the 13 factors compared between the two stocks. Get Spruce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRB vs. The Competition Export to ExcelMetricSpruce BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.06M$813.46M$5.54B$8.95BDividend YieldN/A4.84%5.38%4.08%P/E Ratio-0.081.1027.4020.04Price / Sales0.62220.40419.46118.60Price / CashN/A23.4436.6357.47Price / Book0.046.108.085.67Net Income-$47.92M-$27.81M$3.16B$248.47M7 Day PerformanceN/A0.67%2.12%2.90%1 Month PerformanceN/A7.16%4.43%5.75%1 Year PerformanceN/A7.88%35.62%21.36% Spruce Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRBSpruce Biosciences2.1906 of 5 stars$0.07-0.7%$1.75+2,317.1%-86.2%$3.06M$4.91M-0.0820TRIBTrinity Biotech0.4097 of 5 stars$0.65-0.3%N/A-66.5%$11.77M$61.56M-0.23480Gap UpATHAAthira Pharma2.9161 of 5 stars$0.30+2.4%$11.25+3,625.2%-88.1%$11.52MN/A-0.1540Gap DownBGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002Gap DownBCDABioCardia3.998 of 5 stars$1.95-9.3%$25.00+1,182.1%-29.3%$11.13M$60K-0.8440News CoveragePositive NewsInsider TradeGap UpEQEquillium1.8427 of 5 stars$0.32+1.7%$3.00+851.8%-53.2%$11.07M$41.10M-0.8140Gap UpSNSESensei Biotherapeutics4.2095 of 5 stars$8.58-1.2%$90.00+949.0%-26.5%$10.94MN/A-0.3740Gap DownLPTXLeap Therapeutics1.4408 of 5 stars$0.30+13.5%$3.38+1,036.7%-83.0%$10.84MN/A-0.1740BTAIBioXcel Therapeutics4.3195 of 5 stars$1.81+2.3%$42.60+2,253.6%-89.2%$10.72M$2.27M-0.1390News CoverageGap UpXFORX4 Pharmaceuticals4.7223 of 5 stars$1.90+3.8%$72.33+3,707.0%-87.9%$10.59M$2.56M0.8980News CoverageHigh Trading VolumePHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049 Related Companies and Tools Related Companies Trinity Biotech Competitors Athira Pharma Competitors Bright Green Competitors BioCardia Competitors Equillium Competitors Sensei Biotherapeutics Competitors Leap Therapeutics Competitors BioXcel Therapeutics Competitors X4 Pharmaceuticals Competitors PHAXIAM Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRB) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spruce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spruce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SPRB Stock Alerts